Neurospine Search


Neurospine > Accepted
DOI:    [Accepted]
Published online January 15, 2019.
Acidic Fibroblast Growth Factor in Spinal Cord Injury
Chin-Chu Ko1,2,3  , Tsung-Hsi Tu3,4,5, Jau-Ching Wu2,3,4, Wen-Cheng Huang3,4, Henrich Cheng2,3,4
1Jhong Jheng Spine & Orthopedic Hospital, Kaohsiung, Taiwan
2Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan
3School of Medicine, National Yang-Ming University, Taipei, Taiwan
4Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan
5Taiwan International Graduate Program in Molecular Medicine, National Yang-Ming University and Academia Sinica, Taipei, Taiwan
Corresponding Author:  Wen-Cheng Huang
Tel: +886-2-2875-7718   Fax: +886-2-2875-7702   Email:
Received: September 22, 2018   Revised: December 13, 2018   Accepted: December 26, 2018
Spinal cord injury (SCI), with an incidence rate at 246 per million-person-years for adults in Taiwan, remains a devastating disease in the current era. Elderly men with lower socioeconomic status have an even higher risk for SCI. Despite advances made in medicine and technology to date, there are few effective treatments for SCI due to the limitations in regenerative capacity in the adult central nervous system. There have been experiments and clinical trials aimed at neuro-regeneration in human SCI, which have encompassed cell- and molecule-based therapies. Furthermore, there have been strategies aimed at restoring connection, including autologous peripheral nerve grafts and biomaterial scaffolds which theoretically promote axonal growth. Most of the molecule-based therapies target the modulation of the inhibitory molecules for axonal growth, degradation of glial scarring obstacles, and stimulation of intrinsic regenerative capacity. Among them, acidic fibroblast growth factor (aFGF) has been investigated for nerve repair; it is mitogenic and pluripotent in nature and could enhance axonal growth and mitigate glial scaring. For more than two decades the authors have conducted multiple trials, including human and animal experiments, using aFGF to repair nerve injuries, including central and peripheral nerves. Promising results in using aFGF for neural regeneration have been demonstrated, and future emphasis on aFGF as a neurotrophic factor should warrant more trials and applications. Focusing on aFGF, the current review aimed to summarize the historical evolution of the utilization of aFGF in SCI and nerve injuries, present applications and trials, brief its possible mechanisms, and to provide future perspectives.
Keywords: acidic fibroblast growth factor; spinal cord injury; regeneration

Editorial Office
Department of Neurosurgery, Yonsei University College of Medicine
50-1, Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-2228-2172  E-mail:
The Korean Spinal Neurosurgery Society
#407, Dong-A Villate 2nd Town, 350 Seocho-daero, Seocho-gu, Seoul 06631, Korea
Tel: +82-2-585-5455  Fax: +82-2-2-523-6812  E-mail:
Business License No.: 209-82-62443

Copyright © The Korean Spinal Neurosurgery Society. All rights reserved.

Developed in M2community

Close layer
prev next